Cannabinoids for the management of neuropathic pain: review of clinical effectiveness
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001153
English
Authors' recommendations:
In two five-week RCTs, THC:CBD was more effective than placebo when added to existing therapy for the management of neuropathic pain associated with MS and in patients with neuropathic pain stemming from mixed etiologies. In a longer study (12 weeks) in patients with diabetic neuropathy, there was no difference between THC:CBD and placebo in the management of neuropathic pain. This may suggest that THC:CBD is either not effective in diabetic neuropathy or that the analgesic effects of THC:CBD diminished with longer duration of treatment in this population.Overall, the limited evidence suggests that cannabinoids may provide pain relief in patients withHIV or MS who have neuropathic pain when used as add on therapy.
Details
Project Status:
Completed
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Cannabinoids
- Pain
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.